• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Chan Zuckerberg Initiative to acquire AI startup Meta

Chan Zuckerberg Initiative to acquire AI startup Meta

January 24, 2017
CenterWatch Staff

iGan Partners is thrilled to announce the pending acquisition of its portfolio company, Meta, by the Chan Zuckerberg Initiative. Launched in 2015 by Mark Zuckerberg and Dr. Priscilla Chan, the Chan Zuckerberg Initiative is dedicated to advancing human potential and promoting equal opportunity, with a current focus on scientific research, education, and building strong communities. The goal of their science initiative is to cure, prevent, or manage all diseases by the end of this century.

Meta is Toronto-based technology company that helps researchers understand what is happening globally in science, and shows them where science is headed. Meta uses artificial intelligence to read the world's scientific papers, understand what is in them, and deliver their insights to researchers in real time. This information can help researchers and experts make faster progress in all areas of science to accelerate medical advances.

As part of the Chan Zuckerberg Initiative, Meta's capabilities will get united into a single, powerful tool, and be made available to the entire scientific community. The Chan Zuckerberg Initiative and Meta are committed to offering these tools for free to all researchers.

 "We are very pleased to have supported Meta from the beginning and through the ups and downs of a startup. We believe the Chan Zuckerberg Initiative is the perfect home for Meta and it will form the backbone of the Chan Zuckerberg Initiative's goal to make a dent on disease. We will miss the regular interactions with Sam Molyneux and his team," said Sam Ifergan, president of iGan Partners.

"We are very excited about what lies ahead," said Sam Molyneux, co-founder and CEO of Meta. "Our progress was only possible due to the team, our board, the support of their families and friends, our investors, and the Canadian start-up system."

Meta's earliest backers include iGan Partners who led the seed round and has participated in every financing since. Other investors include Rho Canada Ventures, Solina Chau (Horizons Ventures), Everline Investments and many angels.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing